Details of the Drug Combination

General Information of Drug Combination (ID: DCAB9GX)

Drug Combination Name

CBT-101 CBT-501

Indication

Disease Entry	Status	REF
Solid tumour/cancer	Phase 1	[1]

Component Drugs

CBT-101 DMOTLN4

CBT-501 DMW1OKT

N.A.

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of CBT-101

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
Glaucoma/ocular hypertension	9C61	Discontinued in Phase 2	[2]

CBT-101 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Inhibitor	[1]
------------------------------------------------------------------------------------

Indication(s) of CBT-501

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

CBT-501 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Modulator	[3]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005642)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)